Planet Fitness: Beneficiary of the weight-loss boom?

One of the booming (and at the same time a bit annoying) themes at the moment is weight-loss. Practically no day without such headlines. What in the past was a combination of a relatively clean diet paired with frequent activity to stay in shape, today seems to have shifted towards wonder drugs to do the job. Of course genetics also play a role, but broadly speaking this was the formula. In my view going to “the gym” is unlikely to be replaced by weight-loss drugs, no matter how much space they occupy in the news. To the contrary, Planet Fitness is an interesting case to have an eye on.

Continue reading

Safe 20% with Kenvue?

The case of the world’s biggest pure-play consumer care company, Kenvue, is a special one. What makes it interesting is that despite being the primus inter pares, it fetched a 48.7 billion USD bid in November 2025. However, there’s a notable gap of around 20% between the takeover price and where shares currently trade. Could this be an idea, entirely uncorrelated to the broader market, for 2026 for “safe” 20%, if the deal closes?

Continue reading

Reading the tea leaves of Associated British Foods + new research report

Despite my negative view on food and beverage stocks, I have not given up. Associated British Foods, or ABF in brief, appears to offer one of the better setups on the menu. The maker of Twinings Tea is still family-controlled and it has a clean balance sheet. These two points alone dramatically differentiate it from other troubled competitors. However, ABF itself isn’t free of challenges either. Its “defensive” stock last week collapsed after a disappointing trading update. In this weekly, I take a look at ABF, as there’s a potential catalyst on the horizon. Good news for all my paid-members: I’ve finally found a food stock checking my boxes. My first member eggs-clusive research report for 2026 is out of the cage.

Continue reading

Can this company achieve what hasn’t been done in 20 years?

Everyone is aware of tobacco / cigarette companies and their stocks. For many investors, these are absolute core investments for their stability and high dividends. Against all negativity and a shrinking pool of smokers, tobacco companies managed to survive and thrive. Almost a year ago, my Premium PLUS members received an exclusive report from me with an idea with ties to this sector — but from an entirely different viewpoint. I am making this case public now, discussing the rollercoaster that’s behind us, but also what’s ahead of us.

Continue reading

Conagra Brands: A “defensive” consumer stock with an aggressive balance sheet

One or the other time, I have published a weekly about consumer stocks. My general view has been for years that these names should be avoided, being it food, beverage, or alcohol stocks, partly also household and cleaning producers (except one name I published a research report about, it’s up +22% over the last five months). Investors who bought blindly solely based on past performance have suffered big losses. While hopes for a turnaround to finally arrive continue to be high, there’s little reason to be overly optimistic. These stocks have lost their status as “defensive” core positions not for one, but for several reasons. The case study of Conagra Brands.

Continue reading

Are you buying the past with popular ETFs?

This evergreen topic of active vs. passive investing, respectively stock picking vs. investing in index funds via ETFs, is a clash between two absolutely different philosophies. The only thing that’s certain here is that both parties will likely never agree. Both think they’re right and the opposition is wrong. As a passionate stock picker myself, I was triggered by a recent twitter post that in my view has spread a dangerous and misleading message.

Continue reading

Nine lost years — Bottom in sight for Nestlé?

Since its peak at around 130 CHF per share and a market cap of almost 400 billion CHF, consumer staples heavyweight Nestlé has highly disappointed its fan base of predominantly defensively oriented investors. Who’d have thought that THE core investment in the consumer staples sector (besides Coca-Cola) could see its stock price get almost cut in half? Although I have not written a weekly about Nestlé so far, my readers know that Nestlé has not been interesting all the time. Is it now worth a look?

Continue reading

My next Target for a Dividend Cut is a King

I stick to my view which many investors don’t share: this decade will be remembered as the one where dividends have been cut, not sparing big names. With this, I do not mean the obvious candidates like cyclical commodity producers or European car makers, but the ones where it really hurts (for dividend and income investors). In the past, I have written several weeklies, digging out names with proud series that have come to an end or with a high likelihood will end in the not-too-distant future. My next target is another dividend king.

Continue reading

Has Big Pharma destroyed Shareholder Value (as expected)?

In March 2023, I published a controversial weekly, warning about investments in Big Pharma stocks. This group, often popular among retail investors for their dividends and pretend safety (size, diversification, proven, etc.), was already back then clearly facing a huge wall of painful patent expirations. As I had expected, many of the biggest — and most popular — names have seen their stocks painfully breaking apart while broader markets rose. Time for an update.

Continue reading

Are we in a stock picker’s market?

Last Friday, the newsletter from the Wall Street Journal hit my inbox. It immediately raised my attention as the core topic read Why This Isn’t a ‘Stock Picker’s Market’. Being a passionate stock picker myself, having little left for both, mainstream stocks and passive investing, I cannot let this statement left untouched for obvious reasons.

Continue reading